LogicBio Therapeutics, a preclinical biotech developing gene therapies to treat rare diseases, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering.
The Cambridge, MA-based company was founded in 2014 and plans to list on the Nasdaq under the symbol LOGC. LogicBio filed confidentially on August 13, 2018. Jefferies, Barclays and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.
